Full Text View
Tabular View
No Study Results Posted
Related Studies
Photodynamic Therapy in Occult-Only Lesions (POOL)
This study has been completed.
Study NCT00135837   Information provided by Novartis
First Received: August 24, 2005   Last Updated: June 20, 2006   History of Changes

August 24, 2005
June 20, 2006
June 2003
 
visual acuity measurements, baseline, 12 months
Same as current
Complete list of historical versions of study NCT00135837 on ClinicalTrials.gov Archive Site
visual acuity measurements, fundus photographs and fluorescein angiography at baseline, 12 months; ophthalmic examinations, adverse events, vital signs, concomitant medications, 12 months
Same as current
 
Photodynamic Therapy in Occult-Only Lesions (POOL)
An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

 
Phase IV
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Age-Related Macular Degeneration
Drug: Verteporfin for injection
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
202
 
 

Inclusion Criteria:

  • 50 years or older
  • Must see better or equal to 34 letters (visual acuity)
  • Choroidal neovascularization (CNV) lesion must be occult only

Exclusion Criteria:

  • Evidence of classic CNV in the lesion
  • Prior treatment of disease in study eye
  • Have a history of moderate to severe hepatic impairment

Other protocol-defined exclusion criteria may apply.

Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00135837
 
CBPD952B2401
Novartis
QLT Inc
Study Chair: Novartis Customer Information Novartis
Novartis
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP